|
| 36169779 | Characterizing Unhealthy Alcohol Use Patterns and Their Association with Alcohol Use Reduction and Alcohol Use Disorder During Follow-Up in HIV Care. | AIDS Behav | 2023 |
| 37194051 | Mental health and substance use screening in HIV primary care before and during the early COVID-19 pandemic. | BMC Health Serv Res | 2023 |
| 34816805 | Comparison of dementia incidence and prevalence between individuals with and without HIV infection in primary care from 2000 to 2016. | AIDS | 2022 |
| 36097674 | Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study. | J Int AIDS Soc | 2022 |
| 36094142 | Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE). | J Int AIDS Soc | 2022 |
| 34110752 | Improved Gonorrhea and Chlamydia Testing Among Men Who Have Sex With Men Living With HIV Through Implementation of Self-Collected Tests. | Sex Transm Dis | 2021 |
| 32504574 | Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. | Lancet HIV | 2020 |
| 33067802 | Health System-Based Unhealthy Alcohol Use Screening and Treatment Comparing Demographically Matched Participants With and Without HIV. | Alcohol Clin Exp Res | 2020 |
| 28689453 | Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. | HIV Clin Trials | 2017 |
| 25867913 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. | J Acquir Immune Defic Syndr | 2015 |
| 24670520 | Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. | AIDS | 2014 |
| 25397537 | Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis. | J Int AIDS Soc | 2014 |
| 23651648 | Sex differences matter in the gut: effect on mucosal immune activation and inflammation. | Biol Sex Differ | 2013 |
| 21345945 | The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. | J Virol | 2011 |
| 22189150 | Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. | HIV Clin Trials | 2011 |
| 19704266 | Increased rates of appendicitis in HIV-infected men: 1991-2005. | J Acquir Immune Defic Syndr | 2009 |
| 17959677 | Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. | J Virol | 2008 |
| 19079215 | Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. | Mucosal Immunol | 2008 |
| 16885777 | HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. | J Acquir Immune Defic Syndr | 2006 |
| 17178967 | Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. | Arch Surg | 2006 |
| 16873279 | Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. | J Virol | 2006 |
| 15980151 | Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. | Proc Natl Acad Sci U S A | 2005 |
| 16673835 | A randomized trial of the efficacy of group therapy in changing viral load and CD4 counts in individuals living with HIV infection. | Int J Psychiatry Med | 2005 |
| 16164385 | Social support and maladaptive coping as predictors of the change in physical health symptoms among persons living with HIV/AIDS. | AIDS Patient Care STDS | 2005 |
| 15995959 | HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. | J Infect Dis | 2005 |
| 14557656 | Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. | J Virol | 2003 |
| 3058702 | The Escherichia coli biotin biosynthetic enzyme sequences predicted from the nucleotide sequence of the bio operon. | J Biol Chem | 1988 |
| 3073109 | The nucleotide sequence of the Escherichia coli rts gene. | Gene | 1988 |